Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
INGN logo INGN
Upturn stock ratingUpturn stock rating
INGN logo

Inogen Inc (INGN)

Upturn stock ratingUpturn stock rating
$7.67
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: INGN (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

3 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $11

1 Year Target Price $11

Analysts Price Target For last 52 week
$11 Target price
52w Low $5.7
Current$7.67
52w High $13.33

Analysis of Past Performance

Type Stock
Historic Profit -42.49%
Avg. Invested days 24
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 208.21M USD
Price to earnings Ratio -
1Y Target Price 11
Price to earnings Ratio -
1Y Target Price 11
Volume (30-day avg) 3
Beta 1.72
52 Weeks Range 5.70 - 13.33
Updated Date 08/14/2025
52 Weeks Range 5.70 - 13.33
Updated Date 08/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.06

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-07
When -
Estimate -0.27
Actual -0.15

Profitability

Profit Margin -7.58%
Operating Margin (TTM) -6.64%

Management Effectiveness

Return on Assets (TTM) -6.24%
Return on Equity (TTM) -13.46%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 104818003
Price to Sales(TTM) 0.61
Enterprise Value 104818003
Price to Sales(TTM) 0.61
Enterprise Value to Revenue 0.31
Enterprise Value to EBITDA -17.6
Shares Outstanding 27040400
Shares Floating 23941832
Shares Outstanding 27040400
Shares Floating 23941832
Percent Insiders 12.03
Percent Institutions 72.63

ai summary icon Upturn AI SWOT

Inogen Inc

stock logo

Company Overview

overview logo History and Background

Inogen Inc. was founded in 2001 in California. It designs, develops, manufactures, and markets portable oxygen concentrators (POCs) used by patients with chronic respiratory conditions. Initially, Inogen faced challenges in establishing its POC technology and market adoption, but has since become a significant player in the respiratory care market.

business area logo Core Business Areas

  • POC Sales and Rentals: Inogen's primary business revolves around selling and renting its proprietary POCs. Sales involve direct-to-consumer channels and business-to-business channels such as hospitals, clinics, and distributors. Rentals offer patients a flexible option to use POCs without a full purchase.
  • Services and Accessories: Inogen also offers services and accessories, including product maintenance, extended warranties, replacement parts, and oxygen supplies. These contribute to recurring revenue streams.

leadership logo Leadership and Structure

The leadership team typically consists of a CEO, CFO, COO, and other key executives. The organizational structure follows a functional model with departments for research and development, manufacturing, sales, marketing, finance, and operations. The Board of Directors oversees the company's strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • Inogen One G5: The Inogen One G5 is a highly portable and lightweight oxygen concentrator with intelligent delivery technology. Inogen doesn't publicly provide market share data for specific products. However, Inogen and its main competitors, such as Philips Respironics and ResMed, vie for market share within the overall portable oxygen concentrator market. Competitors include ResMed (RMD), Philips (PHG), and Invacare (IVC).
  • Inogen One G4: The Inogen One G4 is a smaller, more compact POC designed for users needing a highly discreet and portable solution. No specific market share data is available for this product. Competitors include ResMed (RMD), Philips (PHG), and Invacare (IVC).

Market Dynamics

industry overview logo Industry Overview

The respiratory care market is driven by the increasing prevalence of chronic respiratory diseases such as COPD and asthma, coupled with an aging population. The market is expanding due to technological advancements in POCs and growing demand for home healthcare solutions.

Positioning

Inogen positions itself as a leader in portable oxygen therapy, focusing on innovative, lightweight, and user-friendly POCs. Its competitive advantages lie in its proprietary technology, direct-to-consumer sales model, and brand reputation.

Total Addressable Market (TAM)

The global respiratory care devices market is projected to reach hundreds of billions of USD. Inogen is positioned to capture a significant portion of this market by focusing on portable oxygen concentrators and expanding its reach through various sales channels.

Upturn SWOT Analysis

Strengths

  • Proprietary POC technology
  • Direct-to-consumer sales model
  • Lightweight and portable products
  • Strong brand reputation
  • Focus on innovation

Weaknesses

  • Reliance on Medicare reimbursement
  • High marketing and sales expenses
  • Exposure to regulatory changes
  • Concentration of revenue from few products

Opportunities

  • Expanding international presence
  • Developing new respiratory care products
  • Strategic partnerships with healthcare providers
  • Growing demand for home healthcare
  • Increasing awareness of COPD and respiratory diseases

Threats

  • Competition from larger medical device companies
  • Changes in reimbursement policies
  • Technological obsolescence
  • Economic downturns affecting consumer spending
  • Supply chain disruptions

Competitors and Market Share

competitor logo Key Competitors

  • RMD
  • PHG
  • IVC

Competitive Landscape

Inogen's advantages include its lightweight and portable POCs, direct-to-consumer sales model, and strong brand reputation. Disadvantages include competition from larger medical device companies and reliance on reimbursement policies.

Growth Trajectory and Initiatives

Historical Growth: Inogen has historically experienced rapid growth due to increasing adoption of POCs and expansion of its sales channels. However, growth rates have fluctuated due to market conditions and competition.

Future Projections: Future growth projections depend on factors such as regulatory changes, competition, and market demand. Analyst estimates suggest continued growth in the respiratory care market, although specific projections for Inogen vary.

Recent Initiatives: Recent strategic initiatives may include expanding its international presence, developing new products, and strengthening its direct-to-consumer sales model. Check the company website for the latest strategic initiatives.

Summary

Inogen is a key player in the portable oxygen concentrator market, leveraging its proprietary technology and direct sales model. The company faces competition from larger firms and is susceptible to reimbursement policy changes. While Inogen's lightweight products and strong brand are strengths, managing costs and expanding internationally are vital for sustained growth. Inogen needs to look out for changes in government regulation and economic downturns that affect consumer spending.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Industry reports
  • Analyst estimates
  • Company website (Inogen.com)

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market share data and financial metrics may be estimates and subject to change. Investing in stocks involves risks, and past performance is not indicative of future results. Please consult with a financial professional before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Inogen Inc

Exchange NASDAQ
Headquaters Goleta, CA, United States
IPO Launch date 2014-02-14
President, CEO & Director Mr. Kevin R. M. Smith
Sector Healthcare
Industry Medical Devices
Full time employees 766
Full time employees 766

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One and Inogen Rove, an ambulatory solutions for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.